Trial Profile
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Olaratumab (Primary) ; Doxorubicin
- Indications Liposarcoma; Nerve sheath neoplasms; Sarcoma; Soft tissue sarcoma
- Focus Biomarker; Pharmacodynamics
- Acronyms JGDM trial
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 03 Apr 2019 Results assessing biomarker modulation in soft tissue sarcoma patients were presented at the 110th Annual Meeting of the American Association for Cancer Research.
- 21 Feb 2019 Status changed from active, no longer recruiting to completed.
- 04 Feb 2019 Planned End Date changed from 14 Jun 2019 to 21 Jan 2020.